BridgeBio Pharma announced that acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), demonstrated early and sustained kidney-protective effects in clinical trials. The drug caused a reversible dip in kidney filtration rate and reduced urinary albumin levels, indicating direct kidney benefits similar to ACE inhibitors and SGLT2 inhibitors. These kidney effects were linked to improved cardiovascular outcomes, including lower risks of death and hospitalization. Acoramidis is approved in the US and Europe and represents a significant advancement in treating ATTR-CM by protecting both heart and kidney functions.
BridgeBio Pharma secured $1 billion through preferred equity investment led by Sixth Street and HealthCare Royalty to support upcoming drug launches and strengthen its financial position. The funding comes as BridgeBio prepares to launch three potent...
BridgeBio Pharma is rated a Buy due to the commercial launch of Attruby and its promising late-stage pipeline focused on rare genetic diseases. The company's valuation exceeds $14 billion, supported by four potential blockbuster drugs expected by 203...
BridgeBio Pharma announced that the Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia demonstrated significant improvements in height velocity, body proportionality, and arm span compared to placebo. These results, published...
